Galera Therapeutics, Inc. Banner Image

Galera Therapeutics, Inc. has reached its limit for free report views

Work for Galera Therapeutics, Inc.? Upgrade Your Profile and unlock all your annual reports.

Galera Therapeutics, Inc.

  • Ticker GRTX
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Galera Therapeutics, Inc. Logo Image
  • 11-50 Employees
  • Based in Malvern, Pennsylvania
Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer. Galera’s lead product candidate is avasopasem manganese (GC4419), a highly selective small molecule superoxide dismutase (SOD) mimetic initially being developed for theMore reduction of radiation-induced severe oral mucositis (SOM). Avasopasem is being studied in the Phase 3 ROMAN trial for its ability to reduce the incidence and severity of SOM induced by radiotherapy in patients with locally advanced head and neck cancer (HNC), its lead indication.
Galera Therapeutics, Inc.

Most Recent Annual Report

Galera Therapeutics, Inc. MOST RECENT 2019 Annual Report and Form 10K

Report Locked. Galera Therapeutics, Inc. has reached its limit for free report views.